title: Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer.
abstract: OBJECTIVE
  To evaluate the feasibility of S-1 plus cisplatin as adjuvant chemotherapy for stage III gastric cancer after curative resection.
  
  
  METHODS
  Japanese patients with stage III gastric cancer who underwent gastrectomy with D2 lymph node resection were enrolled. Treatment consisted of 3 cycles of S-1 (80 mg/m(2)/day, b.i.d.) for 21 days followed by a 14-day rest, and cisplatin (60 mg/m(2) iv) on day 8. After that, S-1 monotherapy was given on days 1-28 every 6 weeks until 1-year postsurgery. After protocol amendment, the first chemotherapy cycle consisted of S-1 monotherapy; cisplatin was added to cycles 2, 3, and 4, followed by S-1 monotherapy up to 1-year postsurgery. The primary endpoint was the completion rate of three cycles of S-1 plus cisplatin.
  
  
  RESULTS
  A total of 63 enrolled patients have been evaluated. Grade 3/4 toxicities included neutropenia (40%), anorexia (28%), and febrile neutropenia (4%) before protocol amendment (n = 25), and neutropenia (37%), anorexia (8%), and febrile neutropenia (3%) after amendment implementation (n = 38). Excluding ineligible cases, treatment completion rates were 57% (12/21) before and 81% (30/37) after the protocol amendment.
  
  
  CONCLUSIONS
  The amended S-1 plus cisplatin is more feasible than the original protocol because of early dose reduction of S-1 prior to cisplatin addition and greater recovery time from surgery prior to cisplatin. This treatment should be considered as a feasible experimental arm for the next postoperative adjuvant phase III trial.
authors.affiliation: Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan. dtakahari@aichi-cc.jp
authors.forename: D
authors.initials: D
authors.lastname: Takahari
authors.forename: T
authors.initials: T
authors.lastname: Hamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Yoshimura
authors.forename: H
authors.initials: H
authors.lastname: Katai
authors.forename: S
authors.initials: S
authors.lastname: Ito
authors.forename: N
authors.initials: N
authors.lastname: Fuse
authors.forename: T
authors.initials: T
authors.lastname: Kinoshita
authors.forename: H
authors.initials: H
authors.lastname: Yasui
authors.forename: M
authors.initials: M
authors.lastname: Terashima
authors.forename: M
authors.initials: M
authors.lastname: Goto
authors.forename: N
authors.initials: N
authors.lastname: Tanigawa
authors.forename: K
authors.initials: K
authors.lastname: Shirao
authors.forename: T
authors.initials: T
authors.lastname: Sano
authors.forename: M
authors.initials: M
authors.lastname: Sasako
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D010349:Patient Compliance; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin